Open Label Extension Study to ZYN2-CL-03 to Assess the Long Term Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 2)

Trial Profile

Open Label Extension Study to ZYN2-CL-03 to Assess the Long Term Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 2)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Acronyms STAR2
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 03 Dec 2017 Data through nine months of total exposure to ZYN002 (three months of treatment in STAR 1 and six months in STAR 2) presented in a Zynerba Pharmaceuticals Media Release.
    • 03 Dec 2017 According to a Zynerba Pharmaceuticals media release, data through nine months of total exposure to ZYN002 (three months of treatment in STAR 1 and six months in STAR 2) were presented at the 2017 Annual Meeting of the American Epilepsy Society (AES).
    • 01 Aug 2017 According to Zynerba Pharmaceuticals media release, dosing continues in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top